Macrophages are cells of the immune system that protect the host from invading pathogens. But in cancer, macrophages can be “hijacked” by tumors, and made to support their malignant growth and spread. This is a drawback for a major cancer treatment, immunotherapy, which turns the body’s immune system against the tumor. EPFL scientists, working with colleagues at the Roche Innovation Centers in Munich and Basel, have now identified a molecular “switch” that can convert the “hijacked” macrophages into cells that can stimulate the immune system to fight the growth and spread of cancer. The work is published in Nature Cell Biology.
Along with attacking foreign pathogens like bacteria, macrophages also help the body’s organs develop and its wounds heal. Their own behavior is fine-tuned by small molecules that they produce, called microRNAs.
When a tumor begins to develop, macrophages attempt to block its growth. But often tumors hijack them and convert them into what are known as “tumor-associated macrophages”, or TAMs for short.
Now corrupted, TAMs use their microRNAs to shield the tumor from the patient’s immune system, helping it grow and metastasize. This phenomenon is common across many tumor types. It is one of the major obstacles in treating cancer, and often leads to a poor prognosis for the patient.
Michele De Palma’s team at EPFL found how to reclaim TAMs. The researchers genetically modified TAMs to remove their ability to produce microRNAs. As a result, the TAMs were reprogrammed dramatically. Instead of protecting the tumor, the TAMs now signaled the presence of the tumor to the immune system, triggering attacks against it – and did so very efficiently.
Using a bioinformatics approach, the researchers found that the most likely culprit was a small family of microRNAs, called Let-7. This offers a more specific target: blocking Let-7 microRNAs may help instruct the TAMs to stimulate anti-tumor immunity.
Interestingly, the researchers observed that reprogramming TAMs also stops cancer cells from leaving the primary tumor. This could mean that the approach can also prevent tumor metastasis, the most threatening aspect of cancer. Moreover, the researchers found that the re-educated TAMs could enhance the anti-tumoral efficacy of certain cancer immunotherapies, some of which are already approved for patients.
However, more work is needed to translate all these findings to actual therapies, especially since there is currently no way to block the Let-7 microRNAs selectively in TAMs. But De Palma’s lab is now working with bioengineers at EPFL to design drugs that can target the Let-7 microRNAs specifically in the TAMs.
Some of the most promising cancer treatments are immunotherapies, which are based on provoking or enhancing the patient’s immune response against their tumor. “The most exciting finding was that TAM reprogramming greatly improved the efficacy of immunotherapy,” says Michele De Palma. “Our results in experimental models of cancer suggest a new therapeutic strategy based on inhibiting the microRNA machinery – or the Let-7 microRNAs – specifically in the TAMs, which may unleash the power of mainstream immunotherapies, such as immune checkpoint inhibitors”.
Learn more: Reclaiming the immune system’s assault on tumors
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Birch pollen allergen immunotherapy normalizes nasal gene-expression and microbial community on February 19, 2019 at 4:04 pm
According to a new study, birch pollen allergen immunotherapy modifies the gene expression and microbiome profile of the nasal epithelium to correspond to those of healthy controls. Birch pollen aller... […]
- First molecular test that selects immunotherapy for kidney cancer on February 19, 2019 at 1:15 pm
Singapore, February 18, 2019 - Immunotherapy drugs such as PD-L1 checkpoint inhibitors represent the front-line treatment for kidney cancer. But immunotherapy is expensive, benefits only a subset of p... […]
- New machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy on February 19, 2019 at 12:43 pm
SNAs are ball-like forms of DNA and RNA arranged on the surface of a nanoparticle. Credit: Chad Mirkin/Northwestern University Spherical nucleic acids are a class of personalized medicines for ... […]
- Anti-cancer immunotherapy could be used to fight HIV on February 19, 2019 at 10:29 am
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple t... […]
- Global Cancer Immunotherapy Market is Projected to Reach $170.70 Billion by 2028 on February 19, 2019 at 9:00 am
FREMONT, California, Feb. 19, 2019 /PRNewswire/ -- According to a new market intelligence report by BIS Research, titled "Global Cancer Immunotherapy Market - Analysis and Forecast, 2018-2028", the ma... […]
- 'Exciting Times' With Immunotherapy for Kidney Cancer on February 19, 2019 at 8:56 am
San Francisco — Two new combination regimens are set to become new standards of care for the treatment of metastatic renal cell carcinoma (mRCC). The new combinations contain an immunotherapy and a ta... […]
- Using anti-cancer immunotherapy to fight HIV on February 19, 2019 at 8:20 am
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on ... […]
- New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein on February 19, 2019 at 7:10 am
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tum... […]
- Immunotherapy could extend survival for patients with aggressive glioblastoma brain cancer on February 19, 2019 at 4:43 am
Sen. John McCain died after a short battle against glioblastoma brain cancer. Glioblastoma — the aggressive brain cancer that killed Sen. John McCain, Sen. Ted Kennedy and Beau Biden, son of ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market Worth $1.7 Billion by 2025: Grand View Research, Inc. on February 19, 2019 at 2:52 am
SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand ... […]
via Bing News